Helmedix

About

Helmedix develops helminth-derived immune-modulating peptide therapeutics for autoimmune and inflammatory diseases, advancing candidates targeting rheumatoid arthritis, colitis, psoriasis, and multiple sclerosis using UTS ithree–licensed IP.

Mission

Helmedix develops helminth-derived immune-modulating peptide drugs intended to prevent and treat autoimmune and inflammatory diseases. The company's pipeline targets conditions including rheumatoid arthritis, colitis, psoriasis and multiple sclerosis. Its programs are based on intellectual property from the University of Technology Sydney’s ithree institute. Helmedix is led by Stephen Thompson, Director and Partner at Brandon Capital. The company received AU$1.25M to advance lead optimization and pre-clinical development of its immune-modulating peptides. Subject to meeting milestones, Helmedix plans to seek further investment or industry partnerships to progress candidates through clinical development.

Quick Facts